The latest news:

• Tocagen Presents Interim Data from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology (SNO)        Exciting reports from the SNO meeting!   Highlight is almost a  doubling of survival time for patients using Toca511 compared to historical controls. These were small uncontrolled trials but they show enough promise that they justify a large phase 2/3 trial which is starting right now!  (disclaimer: Tocagen is a sponsor of our organization)
  



• Combination of bevacizumab and lomustine with first recurrence of glioblastoma prolongs PFS but not OS         We need to have a discussion about the value of increasing progression free survival (PFS) without increasing overall survival.  (The braintumor treatments group is the best place to discuss it). My thoughts are that  obviously, increasing PFS is good - you feel good for a longer period of time, but perhaps it may be better to try other things instead.  Shoot for increasing both PFS and overall survival.  There are a few interesting trials going on for recurrent GBM, and the Optune device has been shown to increase both PFS and OS.
  



• Groundbreaking Global Brain Cancer Trial Planned        

         I tried to get something very similar off the ground years ago, but couldn't raise the money needed for it.  I had the major brain tumor centers and another brain tumor foundation willing but it was too expensive for us.  I hope this group does well. I think it is the fastest and cheapest way to find the best drugs and combinations.
  

BrainTumor Co-Payment Assistance Program Status:

• OPEN to new applicants